SR

Swathi Rekha Jallepalli

Active Director Director DIN 10685349
DIN 10685349 First appointment Jun 2024 Primary industry Consumer Products
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Swathi Rekha Jallepalli

Data last updated:

Swathi Rekha Jallepalli is a Director at Nephgen Pharmaceuticals Private Limited (since 2024). The company operates in Consumer Products.

DIN 10685349
Primary Designation Director
Industry Consumer Products
First Appointment 27 Jun 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director27 Jun 20242024Active

Board colleagues of Swathi Rekha Jallepalli

NameDINCompanyDesignation
Venkata Durga Prasad Jallepalli10685350Nephgen Pharmaceuticals Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Nephgen Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Swathi Rekha Jallepalli

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Swathi Rekha Jallepalli

Swathi Rekha Jallepalli currently holds 1 directorship: Nephgen Pharmaceuticals Private Limited (Director, since 27 Jun 2024).

Swathi Rekha Jallepalli was first appointed on 27 Jun 2024 as Director at Nephgen Pharmaceuticals Private Limited.

The current boards of Swathi Rekha Jallepalli's companies include Venkata Durga Prasad Jallepalli (Nephgen Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available